Atara Biotherapeutics Names New CEO, Board Changes

Ticker: ATRA · Form: 8-K · Filed: Mar 29, 2024 · CIK: 1604464

Atara Biotherapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAtara Biotherapeutics, INC. (ATRA)
Form Type8-K
Filed DateMar 29, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: leadership-change, executive-appointment, board-of-directors

Related Tickers: ATRA

TL;DR

New CEO Pascal Touchon takes the helm at Atara Bio, replacing himself as CEO but staying on as advisor and board member.

AI Summary

Atara Biotherapeutics, Inc. announced on March 26, 2024, changes in its executive and director roles. Dr. Pascal Touchon has been appointed as the new Chief Executive Officer, succeeding Dr. Pascal Touchon who transitioned to a strategic advisor role. Additionally, Dr. Pascal Touchon has been elected to the Board of Directors.

Why It Matters

This filing indicates a leadership transition at Atara Biotherapeutics, which could signal a shift in strategic direction or operational focus for the company.

Risk Assessment

Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and execution, impacting investor confidence.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Executive Officer of Atara Biotherapeutics?

Dr. Pascal Touchon has been appointed as the new Chief Executive Officer.

What is the effective date of the reported changes?

The date of the earliest event reported is March 26, 2024.

What role did Dr. Pascal Touchon previously hold?

The filing indicates Dr. Pascal Touchon transitioned from his CEO role to a strategic advisor role.

Has the Board of Directors composition changed?

Yes, Dr. Pascal Touchon has been elected to the Board of Directors.

What is the principal executive office address for Atara Biotherapeutics?

The principal executive offices are located at 2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, California 91320.

Filing Stats: 477 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-03-29 16:30:12

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATARA BIOTHERAPEUTICS, INC. Date: March 29, 2024 By: /s/ Amar Murugan Amar Murugan Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing